IVF

INVO Bioscience, Inc. (INVO) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2010. INVO Bioscience, Inc. is a development-stage company focused on the manufacture and sale of the INVOcell device, an assisted reproductive technology designed to provide a lower-cost alternative to in vitro fertilization (IVF). The company holds CE marking for distribution in the European Economic Area and various other international markets but is awaiting FDA clearance for the U.S. market. The company is classified as a "smaller reporting company."

Key Financial Metrics

Note: The net income for the six-month period is primarily driven by a non-cash gain of approximately $1.56 million related to the revaluation of derivative liabilities, offsetting significant operating losses.

Material Changes vs. Prior Period

• Revenue Decline: Revenue for the six months ended June 30, 2010, decreased to $37,993 from $53,445 in the prior year period. This was attributed to smaller international shipments and new distributors ordering smaller initial quantities.
• Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased to $764,226 from $1.1 million in the prior year, largely due to reduced staff (five employees vs. seven) and significantly lower travel costs ($24,000 vs. $119,000).
• Derivative Liability Fluctuation: The company recorded a significant non-cash gain of $1,564,634 due to the decrease in the fair value of derivative liabilities (convertible notes and warrants) as the stock price declined relative to the conversion prices.
• Liquidity Crisis: Cash balances plummeted from $79,052 at year-end 2009 to just $571 as of June 30, 2010.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states that the company's recurring losses, negative cash flows, and working capital deficiency raise substantial doubt about its ability to continue as a going concern. Continued operations depend on raising additional capital.
• Capital Needs: Management estimates a monthly burn rate of approximately $175,000. Without additional funding, the company may need to curtail spending or downsize operations.
• Financing Activities: The company is utilizing a Reserve Equity Financing (REF) agreement with AGS Capital Group (up to $10 million) and has issued convertible notes. In August 2010 (subsequent event), the company raised $50,000 to pay off a line of credit.
• Regulatory Status: The company is pursuing FDA 510(k) clearance, which requires a clinical trial. Management hopes to receive clearance by the end of 2011, contingent on securing at least $1 million in funding by December 31, 2010.
• Legal Proceedings: The company is defending against a lawsuit filed by former employees and a creditor of Medelle Corporation regarding asset transfers. Management believes the claims are without merit.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2010, due to limited resources and a lack of segregation of duties.

Investor Verification Checklist

• Cash Runway: Verify the company's current cash position and immediate ability to meet payroll and operational obligations given the $571 cash balance reported.
• Capital Raising Progress: Confirm the status of the $10 million REF agreement with AGS Capital and any new equity or debt financing secured since the filing date.
• Derivative Liability Volatility: Understand that reported net income is heavily influenced by non-cash accounting adjustments related to derivative liabilities, not operational profitability.
• Regulatory Milestones: Monitor progress on the FDA 510(k) clinical trial and the associated funding requirements.
• Related Party Transactions: Review the extent of debt and equity held by officers and directors (e.g., Dr. Ranoux, Kathleen Karloff) and the terms of these arrangements.